The prognosis of patients with primary resistant or relapsed T-ALL remains poor, and development of

targeted drugs are still necessary. Therefore, new targets must be identified. SOX11 is a transcription

factor. Under physiological conditions, SOX11 is absent in the T-cell lineage, however, SOX11 is

upregulated in a subset of T-ALL cases. We aim to unravel the role of SOX11 in T-ALL.